October 11, 2024

Medical Trend

Medical News and Medical Resources

Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial

Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial



Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial.

Moderna, a pharmaceutical company intricately tied to vaccine technology for pandemics, has announced its plans to move forward with Phase 3 trials for its novel combination injection of seasonal influenza and COVID-19 vaccines, following what they describe as “strong” results in the Phase 1/2 testing.

 

Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial

 

 

This marks a significant relief for the biotech firm, as it had previously experienced disappointment with its earlier combination vaccine, mRNA-1010, during this stage of testing.

Moderna’s CEO, Stéphane Bancel, stated on Wednesday, October 4th, “With today’s positive outcomes for our influenza and COVID-19 combo vaccine, we are set to expand our Phase 3 product lineup. The combination vaccine presents a crucial opportunity to enhance the consumer and healthcare provider experience, improve adherence to public health recommendations, and deliver value to the healthcare system. We are excited to advance the respiratory combo vaccine to the Phase 3 development stage.”

The safety and immunogenicity of the mRNA-1083 vaccine were compared through a randomized, observer-blinded study against the standard flu vaccine, Fluarix, and the enhanced flu vaccine, Fluzone HD, with the former intended for adults aged 50-64 and the latter for those aged 65-79. In both age groups, mRNA-1083 was compared to Moderna’s latest COVID-19 vaccine, Spikevax booster shots.

Moderna reports that the “obtained titers of neutralizing antibodies were similar to or higher than those obtained with two licensed quadrivalent influenza vaccines, and the obtained titers of SARS-CoV-2 neutralizing antibodies were similar to Spikevax two-dose booster.”

In terms of adverse effects, adverse events observed in the trial were similar to those seen with standalone COVID-19 vaccines, mostly mild (Grade 1 or 2) in nature, with less than 4% of individuals reporting more severe Grade 3 events. No new safety concerns were identified for the new combination vaccine.

Moderna plans to initiate Phase 3 trials for mRNA-1083 by the end of this year and aims to secure regulatory approval by 2025.

Bancel added, “We are pleased to advance the respiratory combo vaccine into Phase 3 development and look forward to collaborating with public health officials in addressing the significant seasonal threats these viruses pose to humanity.”

 

 

Promising Results from Moderna Influenza + COVID-19 Combo Vaccine Phase 1/2 Trial

(source:internet, reference only)


Disclaimer of medicaltrend.org


Important Note: The information provided is for informational purposes only and should not be considered as medical advice.